Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, double-blind, placebo-controlled trial to evaluate the
efficacy and safety of velusetrag once a day, compared to placebo, in subjects with CIPO.